Dr. Scott Edmondson obtained his Ph.D. from OSU with Leo Paquette followed by postdoctoral studies with Samuel Danishefsky at Columbia University. In 1998, he joined Merck where he progressed to Director of Chemistry and worked in a range of areas including obesity, diabetes, urology, cardiovascular disease, and infectious disease. He is a co-inventor of JanuviaTM for type 2 diabetes and he led a team to discover vibegron, currently in Phase 3 for the treatment of overactive bladder. Dr. Edmondson has co-authored more than 45 publications and 40 patents. Currently, he works in the oncology group at AstraZeneca where he is Director of Chemistry.